Anti-PM/Scl-100 Ab
Use
Anti-PM/Scl-100 antibodies are associated with polymyositis/scleroderma overlap syndrome, which is characterized by clinical features of both polymyositis and scleroderma. Detection of these antibodies can assist in the diagnosis and management of individuals with suspected connective tissue disease. Presence of these antibodies, particularly in combination with other clinical assays, can help confirm autoimmune disease diagnosis, guide treatment decisions, and facilitate patient monitoring.
Special Instructions
Not provided.
Limitations
The test is not FDA cleared or approved. Results should not be the sole basis for diagnosis or therapeutic decisions. Cross-reaction with antibodies from other autoimmune conditions may occur, and results must be interpreted in conjunction with clinical findings and other laboratory tests. The test does not provide a quantitative analysis for each antibody subtype, and the presence of total antibodies is reported.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 101221-0 - ENA PM-SCL-100 Ab Ser IA-aCnc
- 101221-0 - ENA PM-SCL-100 Ab Ser IA-aCnc
Result Turnaround Time
7-11 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.3 mL
Container
Plastic vial
Collection Instructions
Within 1 hour of collection, centrifuge and aliquot 1 mL of serum into a plastic vial. Send refrigerated.
Causes for Rejection
Gross hemolysis, lipemia, icterus, bacterial contamination
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 60 days |